Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (16004)	2/27/1998 2:40:00 PM
From: Henry Niman	Respond to of 32384

LGND is targeting something like 2 dozen STATs, but the 1:3 ratio is more of a function of the maturity of the technology than the importance of the two technologies. Virtually all (if not all) of the interferons, interleukins, and growth factors act through STATs. In other words, the lion's share of biotechnology's therapeutic products (Epogen, Neupogen, Humalin, Aldesleukin, Myotropin, Avonex, leptin) are inject polypeptide hormones. LGND is looking for small molecules that will mimic these hormones. They have IL-2, IL-4, IL-6? projects. The SBH alliance targets Epogen and a few addition hematopoetic growth factors. They also have the leptin promoter program with LLY as well as the leptin signaling program. The above list is by no means complete.